生物学诱导的悖论性牛皮脱发:一个系统的审查
Yaron Gu1,2, Deshan F Sebaratnam1,2, Mani Makhija3
1Faculty of Medicine and Health, The University of New South Wales, Kensington, New South Wales, Australia.
The Australasian journal of dermatology
|September 13, 2025
概括
悖论性牛皮,通常与TNF-α抑制剂有关,在年轻女性中更为常见. 大多数患者实现了缓解,即使在继续进行生物疗法.
科学领域:
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 牛皮是众所周知的牛皮的并发症.
- 生物疗法,特别是TNF-α抑制剂,对于牛皮是有效的,但很少会诱导悖论性脱发.
研究的目的:
- 系统地审查与生物疗法相关的悖论性牛皮脱发患者的结果.
- 描述这些患者的临床表现和治疗反应.
主要方法:
- 主要研究文章的系统审查.
- 包括来自45项研究的96名患者和一个额外的病例.
- 对患者人口统计学,脱发特征和治疗结果的分析.
主要成果:
- 悖论性牛皮脱发症在年轻的女性患者中患病率更高.
- 瘤坏死因子-α (TNF-α) 抑制剂是最常见的生物触发物.
- 观察到一种混合的炎症透体 (淋巴细胞,血细胞,乙氨基酸细胞),与白发病区分开来.
- 大多数患者经历了缓解,大约三分之一的患者继续进行生物治疗.
结论:
- 悖论性牛皮白是一种已知的生物治疗的不良影响,特别是TNF-α抑制剂.
- 这种情况主要影响年轻女性,并呈现出独特的炎症透.
- 治疗往往是成功的,许多患者在维持生物治疗的同时实现了缓解.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Bioequivalence studies: Biowaivers
229
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
229


